Afficher la couverture 'Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial | Guilhot, Francois' en grand format
/5

0 avis

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Archive ouverte

Guilhot, Francois | Rigal-Huguet, Françoise | Guilhot, Joëlle | Guerci-Bresler, Agnès-Paule | Maloisel, Frédéric | Rea, Delphine | Coiteux, Valérie | Gardembas, Martine | Berthou, Christian | Vekhoff, Anne | Jourdan, Eric | Berger, Marc | Fouillard, Loïc | Alexis, Magda | Legros, Laurence | Rousselot, Philippe | Delmer, Alain | Lenain, Pascal | Escoffre Barbe, Martine | Gyan, Emmanuel | Bulabois, Claude-Eric | Dubruille, Viviane | Joly, Bertrand | Pollet, Bertrand | Cony-Makhoul, Pascale | Johnson-Ansah, Hyacinthe | Mercier, Melanie | Caillot, Denis | Charbonnier, Aude | Kiladjian, Jean-Jacques | Chapiro, Jacques | Penot, Amélie | Dorvaux, Véronique | Vaida, Iona | Santagostino, Alberto | Roy, Lydia | Zerazhi, Hacene | Deconinck, Eric | Maisonneuve, Herve | Plantier, Isabelle | Lebon, Delphine | Arkam, Yazid | Cambier, Nathalie | Ghomari, Kamel | Miclea, Jean-Michel | Glaisner, Sylvie | Cayuela, Jean-Michel | Chomel, Jean-Claude | Muller, Marc | Lhermitte, Ludovic | Delord, Marc | Preudhomme, Claude | Etienne, Gabriel | Mahon, François-Xavier | Nicolini, Franck- Emmanuel

Edité par CCSD ; Springer Nature -

International audience

Consulter en ligne

Suggestions

Du même auteur

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Archive ouverte | Nicolini, Franck Emmanuel | CCSD

International audience

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

Archive ouverte | Rea, Delphine | CCSD

International audience

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Archive ouverte | Letestu, Rémi | CCSD

International audience. Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2...

Chargement des enrichissements...